Company intelligence / Profile preview
Nanjing Chongyuan Biotechnology
Nanjing, Jiangsu, China
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Nanjing RegeneCore Biotech is a clinical-stage biopharmaceutical company specializing in the development of innovative single-domain antibody (sdAb) or nanobody-based therapeutics. As a subsidiary of the YOUNGY Group, the company utilizes its proprietary high-throughput sdAb screening and humanization platforms to target autoimmune diseases, oncology, and neurological disorders. Its lead candidate, RC1416, is a first-in-class bispecific sdAb targeting IL-4Rα and IL-5, currently in Phase II clinical trials for asthma and COPD. The company's pipeline also includes RT2831, a bispecific sdAb for acute myeloid leukemia that has received Orphan Drug Designation from the FDA.
- Therapeutic areas
- OncologyPulmonology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyNanobody therapyCell therapymRNA-based drugsNanoparticle
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Nanjing UniversityNanjing University of Chinese MedicineBinghamton University
Beyond the preview
Go deeper on Nanjing Chongyuan Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Chongyuan Biotechnology.